辰欣药业
(603367)
| 流通市值：66.10亿 | | | 总市值：66.10亿 |
| 流通股本：4.53亿 | | | 总股本：4.53亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 1,693,162,287.42 | 850,351,441.43 | 3,444,716,683.93 | 2,583,779,625.67 |
| 营业总成本 | 1,499,927,455.65 | 690,429,639.56 | 3,089,204,509.21 | 2,227,109,205.83 |
| 其他经营收益 | | | | |
| 营业利润 | 285,419,644.91 | 144,246,680.59 | 499,881,818.61 | 424,292,539.48 |
| 利润总额 | 285,301,527.1 | 143,854,042.99 | 496,194,690.13 | 423,310,097.12 |
| 净利润 | 266,953,312.48 | 132,112,004.57 | 425,618,864.59 | 385,240,056.85 |
| 每股收益 | | | | |
| 其他综合收益 | -1,278,277.75 | 21,033.62 | 58,501.11 | 455,209.39 |
| 综合收益总额 | 265,675,034.73 | 132,133,038.19 | 425,677,365.7 | 385,695,266.24 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 5,786,805,134 | 5,415,948,983.27 | 5,210,179,358.71 | 5,188,278,651.76 |
| 非流动资产: | | | | |
| 非流动资产合计 | 2,048,023,773.43 | 2,240,045,091.65 | 2,387,288,100.33 | 2,432,558,192.02 |
| 资产总计 | 7,834,828,907.43 | 7,655,994,074.92 | 7,597,467,459.04 | 7,620,836,843.78 |
| 流动负债: | | | | |
| 流动负债合计 | 1,276,973,552.47 | 1,164,225,433.83 | 1,223,779,367.78 | 1,282,244,496.69 |
| 非流动负债: | | | | |
| 非流动负债合计 | 134,008,635.41 | 128,931,859.24 | 142,984,347.1 | 144,527,241.51 |
| 负债合计 | 1,410,982,187.88 | 1,293,157,293.07 | 1,366,763,714.88 | 1,426,771,738.2 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 6,381,804,234.91 | 6,321,950,519.07 | 6,191,184,283.25 | 6,152,788,443.87 |
| 股东权益合计 | 6,423,846,719.55 | 6,362,836,781.85 | 6,230,703,744.16 | 6,194,065,105.58 |
| 负债和股东权益合计 | 7,834,828,907.43 | 7,655,994,074.92 | 7,597,467,459.04 | 7,620,836,843.78 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 1,711,642,107.12 | 827,102,097.28 | 3,368,097,453.25 | 2,615,149,005.42 |
| 经营活动现金流出小计 | 1,284,508,782.19 | 634,565,119.54 | 2,901,722,870.75 | 2,020,268,864.11 |
| 经营活动产生的现金流量净额 | 427,133,324.93 | 192,536,977.74 | 466,374,582.5 | 594,880,141.31 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 3,240,439,235.38 | 1,255,730,811.04 | 1,515,907,319.24 | 3,945,190,859.63 |
| 投资活动现金流出小计 | 3,384,023,460.25 | 1,802,906,277.87 | 1,689,727,864.02 | 4,856,227,351.34 |
| 投资活动产生的现金流量净额 | -143,584,224.87 | -547,175,466.83 | -173,820,544.78 | -911,036,491.71 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | - | - | 27,428,633.11 | 15,344,800 |
| 筹资活动现金流出小计 | 83,580,003.97 | 2,182,950.31 | 259,388,761.47 | 171,493,656.71 |
| 筹资活动产生的现金流量净额 | -83,580,003.97 | -2,182,950.31 | -231,960,128.36 | -156,148,856.71 |
| 汇率变动对现金及现金等价物的影响 | -3,337,736.34 | -1,416,275.05 | -793,399.29 | -713,875.76 |
| 现金及现金等价物净增加额 | 196,631,359.75 | -358,237,714.45 | 59,800,510.07 | -473,019,082.87 |
| 期末现金及现金等价物余额 | 1,408,707,092.62 | 853,838,018.42 | 1,180,273,813.96 | 647,454,221.02 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | 196,631,359.75 | - | 59,800,510.07 | - |